Romain BUISSON/LinkedIn
Nov 5, 2025, 05:14
Penumbra Announces Secondary Results of the Ground-Breaking STORM – PE RCT
Romain Buisson, Country Manager (TH-HK cluster) at Penumbra, Inc., shared a post by Penumbra, Inc. on LinkedIn:
”Latest updates in STORM PE
Patient treated with CAVT plus anticoagulation experienced significantly longer distance walked during the 90-day six-minute walk test (472m vs 376m; P = 0.019).
CAVT patients near normalized by 90 days, walking 94% of their predicted walk distance vs 75% in the anticoagulation only arm (P = 0.022)”
Quoting Penumbra, Inc.’s post:
”Penumbra announces secondary results of the ground-breaking STORM-PE RCT at VIVA 2025. Read more here.”
Stay updated with Hemostasis Today.
-
Jan 5, 2026, 15:33Mona Ahmed on Why Some Calcified Nodules Trigger ACS and Others Do Not
-
Jan 5, 2026, 14:17Abdul Mannan – VWF:RCo for Diagnosing von Willebrand Disease: That Test Might Be Failing Your Patients
-
Jan 5, 2026, 13:57Ewang Yemi: CAD is Real and Dangerous – Keep Your Heart Beating
-
Jan 5, 2026, 13:42Dr. Martha Boeckenfeld Shares VetiGel Creation Experiment: How A 17-Year-Old Mixed Algae in a Small Hidden Lab
-
Jan 5, 2026, 12:55Chokri Ben Lamine Explains Washed PRBCs!
-
Jan 5, 2026, 12:30ASH: Be Part of The Next Cohort of Hematology Quality Improvement Leaders
-
Jan 5, 2026, 09:59WFH Released New Evidence-Based Guidelines on AAV Gene Therapy for Hemophilia
-
Jan 5, 2026, 09:51Pete Stibbs: We Still Tend to Talk About VTE Like It’s a Plumbing Problem
-
Jan 5, 2026, 09:40Christopher Pittman on Treating Varicose Veins Before Knee or Hip Replacement